Possible	JJ
involvement	NN
of	IN
pirfenidone	NN
metabolites	NNS
in	IN
the	DT
antifibrotic	JJ
action	NN
of	IN
a	DT
therapy	NN
for	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
.	.

Pirfenidone	NN
(	(
PFD	NN
)	)
is	VBZ
the	DT
first	JJ
and	CC
only	RB
clinically	RB
used	VBN
antifibrotic	JJ
drug	NN
for	IN
the	DT
treatment	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

This	DT
study	NN
evaluated	VBD
the	DT
antifibrotic	JJ
effects	NNS
of	IN
two	CD
metabolites	NNS
of	IN
PFD	NN
,	,
5-hydroxypirfenidone	NN
(	(
PFD-OH	NN
)	)
and	CC
5-carboxypirfenidone	NN
(	(
PFD-COOH	NN
)	)
,	,
on	IN
WI-38	NN
cells	NNS
in	IN
an	DT
in	FW
vitro	FW
lung	NN
fibroblast	NN
model	NN
.	.

The	DT
inhibitory	JJ
effects	NNS
of	IN
PFD-OH	NN
and	CC
PFD-COOH	NN
on	IN
transforming-growth-factor-b1	NN
(	(
TGF-b1	NN
)	)
-	:
induced	VBN
collagen	NN
synthesis	NN
in	IN
WI-38	NN
cells	NNS
were	VBD
evaluated	VBN
by	IN
measuring	VBG
intracellular	JJ
hydroxyproline	NN
,	,
a	DT
major	JJ
component	NN
of	IN
the	DT
protein	NN
collagen	NN
.	.

PFD-OH	NN
and	CC
PFD-COOH	NN
at	IN
300	CD
and	CC
1000	CD
M	NN
concentrations	NNS
significantly	RB
decreased	VBD
the	DT
TGF-b1-induced	JJ
hydroxyproline	NN
content	NN
in	IN
WI-38	NN
cells	NNS
.	.

These	DT
results	NNS
indicate	VBP
that	IN
PFD-OH	NN
and	CC
PFD-COOH	NN
have	VBP
antifibrotic	JJ
activities	NNS
,	,
which	WDT
inhibit	VBP
collagen	NN
synthesis	NN
in	IN
fibroblasts	NNS
.	.

This	DT
study	NN
suggests	VBZ
that	IN
the	DT
concentrations	NNS
of	IN
PFD	NN
and	CC
its	PRP$
metabolites	NNS
should	MD
be	VB
considered	VBN
in	IN
clinical	JJ
therapy	NN
for	IN
IPF	NN
.	.

